Search

Your search keyword '"Quaresmini G."' showing total 68 results
Start Over Author "Quaresmini G."
68 results on '"Quaresmini G."'

1. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Author

Tedeschi, A, Frustaci, A, Condoluci, A, Coscia, M, Chiarle, R, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfò, L, Catania, G, Deodato, M, Jones, R, Tabanelli, V, Griggio, V, Stüssi, G, Calleri, A, Pini, K, Cairoli, R, Zenz, T, Signori, A, Zucca, E, Rossi, D, Montillo, M, Tedeschi, Alessandra, Frustaci, Anna Maria, Condoluci, Adalgisa, Coscia, Marta, Chiarle, Roberto, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Catania, Gioacchino, Deodato, Marina, Jones, Rebecca, Tabanelli, Valentina, Griggio, Valentina, Stüssi, Georg, Calleri, Angelica, Pini, Katia, Cairoli, Roberto, Zenz, Thorsten, Signori, Alessio, Zucca, Emanuele, Rossi, Davide, Montillo, Marco, Tedeschi, A, Frustaci, A, Condoluci, A, Coscia, M, Chiarle, R, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfò, L, Catania, G, Deodato, M, Jones, R, Tabanelli, V, Griggio, V, Stüssi, G, Calleri, A, Pini, K, Cairoli, R, Zenz, T, Signori, A, Zucca, E, Rossi, D, Montillo, M, Tedeschi, Alessandra, Frustaci, Anna Maria, Condoluci, Adalgisa, Coscia, Marta, Chiarle, Roberto, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Catania, Gioacchino, Deodato, Marina, Jones, Rebecca, Tabanelli, Valentina, Griggio, Valentina, Stüssi, Georg, Calleri, Angelica, Pini, Katia, Cairoli, Roberto, Zenz, Thorsten, Signori, Alessio, Zucca, Emanuele, Rossi, Davide, and Montillo, Marco

Published
2024

2. EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Author

Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfò, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stüssi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci A. M., Montillo M., Rossi D., Zinzani P. L., Motta M., Gaidano G., Quaresmini G., Scarfò L., Pietrasanta D., Coscia M., Deodato M., Zamprogna G., Cairoli R., Stüssi G., Zucca E., Pileri S., Zenz T., Tedeschi A., Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfò, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stüssi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci A. M., Montillo M., Rossi D., Zinzani P. L., Motta M., Gaidano G., Quaresmini G., Scarfò L., Pietrasanta D., Coscia M., Deodato M., Zamprogna G., Cairoli R., Stüssi G., Zucca E., Pileri S., Zenz T., and Tedeschi A.

Published
2023

3. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome

Author

Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfo, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stussi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stussi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, Tedeschi, Alessandra, Frustaci, A, Montillo, M, Rossi, D, Zinzani, P, Motta, M, Gaidano, G, Quaresmini, G, Scarfo, L, Pietrasanta, D, Coscia, M, Deodato, M, Zamprogna, G, Cairoli, R, Stussi, G, Zucca, E, Pileri, S, Zenz, T, Tedeschi, A, Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfo, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stussi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, and Tedeschi, Alessandra

Published
2023

4. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study

Author

Autore, Francesco, Innocenti, Idanna, Reda, G., Visentin, A., Vitale, C., Piciocchi, A., Fresa, Alberto, Leone, M. M. A., Farina, L., Quaresmini, G., Barate, C., Giordano, A., Ferrari, A., Angeletti, I., De Paolis, M. R., Malerba, L., Chiurazzi, F., Loseto, G., Catania, G., Sportoletti, P., Scortechini, I., Moia, R., Gentile, M., Rigolin, G. M., Mattiello, V., Gattei, V., Coscia, M., Trentin, L., Foa, Robin, Cuneo, A., Laurenti, Luca, Autore F., Innocenti I., Fresa A., Foa R., Laurenti L. (ORCID:0000-0002-8327-1396), Autore, Francesco, Innocenti, Idanna, Reda, G., Visentin, A., Vitale, C., Piciocchi, A., Fresa, Alberto, Leone, M. M. A., Farina, L., Quaresmini, G., Barate, C., Giordano, A., Ferrari, A., Angeletti, I., De Paolis, M. R., Malerba, L., Chiurazzi, F., Loseto, G., Catania, G., Sportoletti, P., Scortechini, I., Moia, R., Gentile, M., Rigolin, G. M., Mattiello, V., Gattei, V., Coscia, M., Trentin, L., Foa, Robin, Cuneo, A., Laurenti, Luca, Autore F., Innocenti I., Fresa A., Foa R., and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Clinical or biological parameters useful to predict progression during treatment in real-life setting with ibrutinib, idelalisib and venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) are still debated. We conducted a multi-center retrospective study on CLL patients treated with ibrutinib and/or idelalisib who were switched to venetoclax for progression or due to adverse events to identify any clinical and/or biological parameters useful to predict progression during treatment with venetoclax. Of all the 128 evaluable patients, 81 had received ibrutinib prior to switching to venetoclax, 35 had received idelalisib and 12 both. When comparing the three subgroups, we did not notice any statistical difference in terms of clinical or biological features. No variable at baseline and at different time points during the follow-up (at 6, 12, 18 and 24 months) was found to predict progression nor to have significance for Progression Free Survival (PFS) in the ibrutinib group and in the idelalisib group and in subgroups according to the line of treatment. Analyzing the data of the venetoclax treatment, after a median follow up of 14.3 months, median PFS was not reached and estimated 3-year PFS was 54%. Of the 128 patients treated with venetoclax, 28 (22%) experienced progressive disease. At multivariate analysis for predictive factors for progression, lymph node diameter >56.5 mm before starting treatment emerged as an independent risk factor for progression. The lymph node predictive role for progression during venetoclax treatment could be a new parameter that deserves to be investigate in future studies.

Published
2023

5. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, D. Milic, N. Chatzikonstantinou, T. Scarfò, L. Otasevic, V. Rajovic, N. Allsup, D. Alonso Cabrero, A. Andres, M. Baile Gonzales, M. Capasso, A. Collado, R. Cordoba, R. Cuéllar-García, C. Correa, J.G. De Paoli, L. De Paolis, M.R. Del Poeta, G. Dimou, M. Doubek, M. Efstathopoulou, M. El-Ashwah, S. Enrico, A. Espinet, B. Farina, L. Ferrari, A. Foglietta, M. Lopez-Garcia, A. García-Marco, J.A. García-Serra, R. Gentile, M. Gimeno, E. da Silva, M.G. Gutwein, O. Hakobyan, Y.K. Herishanu, Y. Hernández-Rivas, J.Á. Herold, T. Itchaki, G. Jaksic, O. Janssens, A. Kalashnikova, O.B. Kalicińska, E. Kater, A.P. Kersting, S. Koren-Michowitz, M. Labrador, J. Lad, D. Laurenti, L. Fresa, A. Levin, M.-D. Mayor Bastida, C. Malerba, L. Marasca, R. Marchetti, M. Marquet, J. Mihaljevic, B. Milosevic, I. Mirás, F. Morawska, M. Motta, M. Munir, T. Murru, R. Nunes, R. Olivieri, J. Pavlovsky, M.A. Piskunova, I. Popov, V.M. Quaglia, F.M. Quaresmini, G. Reda, G. Rigolin, G.M. Shrestha, A. Šimkovič, M. Smirnova, S. Špaček, M. Sportoletti, P. Stanca, O. Stavroyianni, N. Te Raa, D. Tomic, K. Tonino, S. Trentin, L. Van Der Spek, E. van Gelder, M. Varettoni, M. Visentin, A. Vitale, C. Vukovic, V. Wasik-Szczepanek, E. Wróbel, T. Segundo, L.Y.S. Yassin, M. Coscia, M. Rambaldi, A. Montserrat, E. Foà, R. Cuneo, A. Carrier, M. Ghia, P. Stamatopoulos, K. and Antic, D. Milic, N. Chatzikonstantinou, T. Scarfò, L. Otasevic, V. Rajovic, N. Allsup, D. Alonso Cabrero, A. Andres, M. Baile Gonzales, M. Capasso, A. Collado, R. Cordoba, R. Cuéllar-García, C. Correa, J.G. De Paoli, L. De Paolis, M.R. Del Poeta, G. Dimou, M. Doubek, M. Efstathopoulou, M. El-Ashwah, S. Enrico, A. Espinet, B. Farina, L. Ferrari, A. Foglietta, M. Lopez-Garcia, A. García-Marco, J.A. García-Serra, R. Gentile, M. Gimeno, E. da Silva, M.G. Gutwein, O. Hakobyan, Y.K. Herishanu, Y. Hernández-Rivas, J.Á. Herold, T. Itchaki, G. Jaksic, O. Janssens, A. Kalashnikova, O.B. Kalicińska, E. Kater, A.P. Kersting, S. Koren-Michowitz, M. Labrador, J. Lad, D. Laurenti, L. Fresa, A. Levin, M.-D. Mayor Bastida, C. Malerba, L. Marasca, R. Marchetti, M. Marquet, J. Mihaljevic, B. Milosevic, I. Mirás, F. Morawska, M. Motta, M. Munir, T. Murru, R. Nunes, R. Olivieri, J. Pavlovsky, M.A. Piskunova, I. Popov, V.M. Quaglia, F.M. Quaresmini, G. Reda, G. Rigolin, G.M. Shrestha, A. Šimkovič, M. Smirnova, S. Špaček, M. Sportoletti, P. Stanca, O. Stavroyianni, N. Te Raa, D. Tomic, K. Tonino, S. Trentin, L. Van Der Spek, E. van Gelder, M. Varettoni, M. Visentin, A. Vitale, C. Vukovic, V. Wasik-Szczepanek, E. Wróbel, T. Segundo, L.Y.S. Yassin, M. Coscia, M. Rambaldi, A. Montserrat, E. Foà, R. Cuneo, A. Carrier, M. Ghia, P. Stamatopoulos, K.

Abstract

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occu

Published
2022

6. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, D., Milic, N., Chatzikonstantinou, T., Scarfo, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuellar-Garcia, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., Efstathopoulou, M., El-Ashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., Lopez-Garcia, A., Garcia-Marco, J. A., Garcia-Serra, R., Gentile, Marino, Gimeno, E., da Silva, M. G., Gutwein, O., Hakobyan, Y. K., Herishanu, Y., Hernandez-Rivas, J. A., Herold, T., Itchaki, G., Jaksic, O., Janssens, A., Kalashnikova, O. B., Kalicinska, E., Kater, A. P., Kersting, S., Koren-Michowitz, M., Labrador, J., Lad, D., Laurenti, Luca, Fresa, Alberto, Levin, M. -D., Mayor Bastida, C., Malerba, L., Marasca, R., Marchetti, M., Marquet, J., Mihaljevic, B., Milosevic, I., Miras, F., Morawska, M., Motta, M., Munir, T., Murru, R., Nunes, R., Olivieri, J., Pavlovsky, M. A., Piskunova, I., Popov, V. M., Quaglia, F. M., Quaresmini, G., Reda, G., Rigolin, G. M., Shrestha, A., Simkovic, M., Smirnova, S., Spacek, M., Sportoletti, P., Stanca, O., Stavroyianni, N., Te Raa, D., Tomic, K., Tonino, S., Trentin, L., Van Der Spek, E., van Gelder, M., Varettoni, M., Visentin, A., Vitale, C., Vukovic, Vladimir, Wasik-Szczepanek, E., Wrobel, T., Segundo, L. Y. S., Yassin, M., Coscia, M., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Carrier, M., Ghia, P., Stamatopoulos, K., Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Fresa A., Vukovic V. (ORCID:0000-0002-9561-7825), Foa R., Antic, D., Milic, N., Chatzikonstantinou, T., Scarfo, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuellar-Garcia, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., Efstathopoulou, M., El-Ashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., Lopez-Garcia, A., Garcia-Marco, J. A., Garcia-Serra, R., Gentile, Marino, Gimeno, E., da Silva, M. G., Gutwein, O., Hakobyan, Y. K., Herishanu, Y., Hernandez-Rivas, J. A., Herold, T., Itchaki, G., Jaksic, O., Janssens, A., Kalashnikova, O. B., Kalicinska, E., Kater, A. P., Kersting, S., Koren-Michowitz, M., Labrador, J., Lad, D., Laurenti, Luca, Fresa, Alberto, Levin, M. -D., Mayor Bastida, C., Malerba, L., Marasca, R., Marchetti, M., Marquet, J., Mihaljevic, B., Milosevic, I., Miras, F., Morawska, M., Motta, M., Munir, T., Murru, R., Nunes, R., Olivieri, J., Pavlovsky, M. A., Piskunova, I., Popov, V. M., Quaglia, F. M., Quaresmini, G., Reda, G., Rigolin, G. M., Shrestha, A., Simkovic, M., Smirnova, S., Spacek, M., Sportoletti, P., Stanca, O., Stavroyianni, N., Te Raa, D., Tomic, K., Tonino, S., Trentin, L., Van Der Spek, E., van Gelder, M., Varettoni, M., Visentin, A., Vitale, C., Vukovic, Vladimir, Wasik-Szczepanek, E., Wrobel, T., Segundo, L. Y. S., Yassin, M., Coscia, M., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Carrier, M., Ghia, P., Stamatopoulos, K., Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Fresa A., Vukovic V. (ORCID:0000-0002-9561-7825), and Foa R.

Abstract

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occu

Published
2022

7. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic D, Milic N, Chatzikonstantinou T, Scarfò L, Otasevic V, Rajovic N, Allsup D, Alonso Cabrero A, Andres M, Baile Gonzales M, Capasso A, Collado R, Cordoba R, Cuéllar-García C, Correa JG, De Paoli L, De Paolis MR, Del Poeta G, Dimou M, Doubek M, Efstathopoulou M, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Lopez-Garcia A, García-Marco JA, García-Serra R, Gentile M, Gimeno E, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Kater AP, Kersting S, Koren- Michowitz M, Labrador J, Lad D, Laurenti L, Fresa A, Levin MD, Mayor Bastida C, Malerba L, Marasca R, Marchetti M, Marquet J, Mihaljevic B, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Nunes R, Olivieri J, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Reda G, Rigolin GM, Shrestha A, Šimkovič M, Smirnova S, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Te Raa D, Tomic K, Tonino S, Trentin L, Van Der Spek E, van Gelder M, Varettoni M, Visentin A, Vitale C, Vukovic V, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Carrier M, Ghia P, Stamatopoulos K.

Subjects
Age, Anticoagulation therapy, Bleeding, CLL, COVID-19, D-dimer, LMWH, Thromboprophylaxis, Thrombosis
Abstract

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment- related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS- CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C- reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR = 1.022, 95%CI 1.007‒1.038 and OR = 1.025, 95%CI 1.001‒1.051, respectively), while thromboprophylaxis use was protective (OR = 0.199, 95%CI 0.061‒0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR = 1.062, 95%CI 1.017-1.109 and OR = 2.438, 95%CI 1.023-5.813, respectively). Conclusions: Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration.

Published
2022

9. Rapid reconstitution of functionally active 6-sulfoLacNAc+ dendritic cells (slanDCs) of donor origin following allogeneic haematopoietic stem cell transplant

Author

Mimiola, E., Marini, O., Perbellini, O., Micheletti, A., Vermi, W., Lonardi, S., Costantini, C., Meneghelli, E., Andreini, A., Bonetto, C., Vassanelli, A., Cantini, M., Zoratti, E., Massi, D., Zamoʼ, A., Leso, A., Quaresmini, G., Benedetti, F., Pizzolo, G., Cassatella, M. A., and Tecchio, C.

Published
2014
Full Text
View/download PDF

11. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report

Author

Cuneo, A., Rigolin, G. M., Coscia, M., Quaresmini, G., Scarfo, L., Mauro, F. R., Motta, M., Quaglia, F. M., Trentin, L., Ferrario, Alberto Alfredo, Laurenti, Luca, Reda, G., Ferrari, A., Pietrasanta, D., Sportoletti, P., Re, F., De Paoli, L., Foglietta, M., Giordano, A., Marchetti, M., Farina, L., Del Poeta, G., Varettoni, M., Chiurazzi, F., Marasca, R., Malerba, L., Ibatici, A., Tisi, Maria Chiara, Stefoni, V., Leone, M., Barate, C., Olivieri, J., Murru, R., Gentile, Marino, Sanna, A., Gozzetti, A., Gattei, V., Gottardi, D., Derenzini, E., Levato, L., Orsucci, L., Penna, G., Chiarenza, A., Foa, Robin, Ferrario A., Laurenti L. (ORCID:0000-0002-8327-1396), Tisi M. C., Gentile M., Foa R., Cuneo, A., Rigolin, G. M., Coscia, M., Quaresmini, G., Scarfo, L., Mauro, F. R., Motta, M., Quaglia, F. M., Trentin, L., Ferrario, Alberto Alfredo, Laurenti, Luca, Reda, G., Ferrari, A., Pietrasanta, D., Sportoletti, P., Re, F., De Paoli, L., Foglietta, M., Giordano, A., Marchetti, M., Farina, L., Del Poeta, G., Varettoni, M., Chiurazzi, F., Marasca, R., Malerba, L., Ibatici, A., Tisi, Maria Chiara, Stefoni, V., Leone, M., Barate, C., Olivieri, J., Murru, R., Gentile, Marino, Sanna, A., Gozzetti, A., Gattei, V., Gottardi, D., Derenzini, E., Levato, L., Orsucci, L., Penna, G., Chiarenza, A., Foa, Robin, Ferrario A., Laurenti L. (ORCID:0000-0002-8327-1396), Tisi M. C., Gentile M., and Foa R.

Abstract

n/a

Published
2021

13. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfò, L. Chatzikonstantinou, T. Rigolin, G.M. Quaresmini, G. Motta, M. Vitale, C. Garcia-Marco, J.A. Hernández-Rivas, J.Á. Mirás, F. Baile, M. Marquet, J. Niemann, C.U. Reda, G. Munir, T. Gimeno, E. Marchetti, M. Quaglia, F.M. Varettoni, M. Delgado, J. Iyengar, S. Janssens, A. Marasca, R. Ferrari, A. Cuéllar-García, C. Itchaki, G. Špaček, M. De Paoli, L. Laurenti, L. Levin, M.-D. Lista, E. Mauro, F.R. Šimkovič, M. Van Der Spek, E. Vandenberghe, E. Trentin, L. Wasik-Szczepanek, E. Ruchlemer, R. Bron, D. De Paolis, M.R. Del Poeta, G. Farina, L. Foglietta, M. Gentile, M. Herishanu, Y. Herold, T. Jaksic, O. Kater, A.P. Kersting, S. Malerba, L. Orsucci, L. Popov, V.M. Sportoletti, P. Yassin, M. Pocali, B. Barna, G. Chiarenza, A. dos Santos, G. Nikitin, E. Andres, M. Dimou, M. Doubek, M. Enrico, A. Hakobyan, Y. Kalashnikova, O. Ortiz Pareja, M. Papaioannou, M. Rossi, D. Shah, N. Shrestha, A. Stanca, O. Stavroyianni, N. Strugov, V. Tam, C. Zdrenghea, M. Coscia, M. Stamatopoulos, K. Rossi, G. Rambaldi, A. Montserrat, E. Foà, R. Cuneo, A. Ghia, P. and Scarfò, L. Chatzikonstantinou, T. Rigolin, G.M. Quaresmini, G. Motta, M. Vitale, C. Garcia-Marco, J.A. Hernández-Rivas, J.Á. Mirás, F. Baile, M. Marquet, J. Niemann, C.U. Reda, G. Munir, T. Gimeno, E. Marchetti, M. Quaglia, F.M. Varettoni, M. Delgado, J. Iyengar, S. Janssens, A. Marasca, R. Ferrari, A. Cuéllar-García, C. Itchaki, G. Špaček, M. De Paoli, L. Laurenti, L. Levin, M.-D. Lista, E. Mauro, F.R. Šimkovič, M. Van Der Spek, E. Vandenberghe, E. Trentin, L. Wasik-Szczepanek, E. Ruchlemer, R. Bron, D. De Paolis, M.R. Del Poeta, G. Farina, L. Foglietta, M. Gentile, M. Herishanu, Y. Herold, T. Jaksic, O. Kater, A.P. Kersting, S. Malerba, L. Orsucci, L. Popov, V.M. Sportoletti, P. Yassin, M. Pocali, B. Barna, G. Chiarenza, A. dos Santos, G. Nikitin, E. Andres, M. Dimou, M. Doubek, M. Enrico, A. Hakobyan, Y. Kalashnikova, O. Ortiz Pareja, M. Papaioannou, M. Rossi, D. Shah, N. Shrestha, A. Stanca, O. Stavroyianni, N. Strugov, V. Tam, C. Zdrenghea, M. Coscia, M. Stamatopoulos, K. Rossi, G. Rambaldi, A. Montserrat, E. Foà, R. Cuneo, A. Ghia, P.

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.

Published
2020

14. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfo, L, Chatzikonstantinou, T, Rigolin, GM, Quaresmini, G, Motta, M, Vitale, C, Garcia-Marco, JA, Hernandez-Rivas, JA, Miras, F, Baile, M, Marquet, J, Niemann, CU, Reda, G, Munir, T, Gimeno, E, Marchetti, M, Quaglia, FM, Varettoni, M, Delgado, J, Iyengar, S, Janssens, A, Marasca, R, Ferrari, A, Cuellar-Garcia, C, Itchaki, G, Spacek, M, De Paoli, L, Laurenti, L, Levin, M-D, Lista, E, Mauro, FR, Simkovic, M, Van Der Spek, E, Vandenberghe, E, Trentin, L, Wasik-Szczepanek, E, Ruchlemer, R, Bron, D, De Paolis, MR, Del Poeta, G, Farina, L, Foglietta, M, Gentile, M, Herishanu, Y, Herold, T, Jaksic, O, Kater, AP, Kersting, S, Malerba, L, Orsucci, L, Popov, VM, Sportoletti, P, Yassin, M, Pocali, B, Barna, G, Chiarenza, A, dos Santos, G, Nikitin, E, Andres, M, Dimou, M, Doubek, M, Enrico, A, Hakobyan, Y, Kalashnikova, O, Ortiz Pareja, M, Papaioannou, M, Rossi, D, Shah, N, Shrestha, A, Stanca, O, Stavroyianni, N, Strugov, V, Tam, C, Zdrenghea, M, Coscia, M, Stamatopoulos, K, Rossi, G, Rambaldi, A, Montserrat, E, Foa, R, Cuneo, A, Ghia, P, Scarfo, L, Chatzikonstantinou, T, Rigolin, GM, Quaresmini, G, Motta, M, Vitale, C, Garcia-Marco, JA, Hernandez-Rivas, JA, Miras, F, Baile, M, Marquet, J, Niemann, CU, Reda, G, Munir, T, Gimeno, E, Marchetti, M, Quaglia, FM, Varettoni, M, Delgado, J, Iyengar, S, Janssens, A, Marasca, R, Ferrari, A, Cuellar-Garcia, C, Itchaki, G, Spacek, M, De Paoli, L, Laurenti, L, Levin, M-D, Lista, E, Mauro, FR, Simkovic, M, Van Der Spek, E, Vandenberghe, E, Trentin, L, Wasik-Szczepanek, E, Ruchlemer, R, Bron, D, De Paolis, MR, Del Poeta, G, Farina, L, Foglietta, M, Gentile, M, Herishanu, Y, Herold, T, Jaksic, O, Kater, AP, Kersting, S, Malerba, L, Orsucci, L, Popov, VM, Sportoletti, P, Yassin, M, Pocali, B, Barna, G, Chiarenza, A, dos Santos, G, Nikitin, E, Andres, M, Dimou, M, Doubek, M, Enrico, A, Hakobyan, Y, Kalashnikova, O, Ortiz Pareja, M, Papaioannou, M, Rossi, D, Shah, N, Shrestha, A, Stanca, O, Stavroyianni, N, Strugov, V, Tam, C, Zdrenghea, M, Coscia, M, Stamatopoulos, K, Rossi, G, Rambaldi, A, Montserrat, E, Foa, R, Cuneo, A, and Ghia, P

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Published
2020

15. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfo, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernandez-Rivas, J. A., Miras, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., Iyengar, S., Janssens, A., Marasca, R., Ferrari, A., Cuellar-Garcia, C., Itchaki, G., Spacek, M., De Paoli, L., Laurenti, Luca, Levin, M. -D., Lista, E., Mauro, F. R., Simkovic, M., Van Der Spek, E., Vandenberghe, E., Trentin, L., Wasik-Szczepanek, E., Ruchlemer, R., Bron, D., De Paolis, M. R., Del Poeta, G., Farina, L., Foglietta, M., Gentile, Marino, Herishanu, Y., Herold, T., Jaksic, O., Kater, A. P., Kersting, S., Malerba, L., Orsucci, L., Popov, V. M., Sportoletti, P., Yassin, M., Pocali, B., Barna, G., Chiarenza, A., dos Santos, G., Nikitin, E., Andres, M., Dimou, M., Doubek, M., Enrico, A., Hakobyan, Y., Kalashnikova, O., Ortiz Pareja, M., Papaioannou, M., Rossi, Dario, Shah, N., Shrestha, A., Stanca, O., Stavroyianni, N., Strugov, V., Tam, C., Zdrenghea, M., Coscia, M., Stamatopoulos, K., Rossi, G., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Ghia, P., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Rossi D., Foa R., Scarfo, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernandez-Rivas, J. A., Miras, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., Iyengar, S., Janssens, A., Marasca, R., Ferrari, A., Cuellar-Garcia, C., Itchaki, G., Spacek, M., De Paoli, L., Laurenti, Luca, Levin, M. -D., Lista, E., Mauro, F. R., Simkovic, M., Van Der Spek, E., Vandenberghe, E., Trentin, L., Wasik-Szczepanek, E., Ruchlemer, R., Bron, D., De Paolis, M. R., Del Poeta, G., Farina, L., Foglietta, M., Gentile, Marino, Herishanu, Y., Herold, T., Jaksic, O., Kater, A. P., Kersting, S., Malerba, L., Orsucci, L., Popov, V. M., Sportoletti, P., Yassin, M., Pocali, B., Barna, G., Chiarenza, A., dos Santos, G., Nikitin, E., Andres, M., Dimou, M., Doubek, M., Enrico, A., Hakobyan, Y., Kalashnikova, O., Ortiz Pareja, M., Papaioannou, M., Rossi, Dario, Shah, N., Shrestha, A., Stanca, O., Stavroyianni, N., Strugov, V., Tam, C., Zdrenghea, M., Coscia, M., Stamatopoulos, K., Rossi, G., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Ghia, P., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Rossi D., and Foa R.

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Published
2020

16. PS1161 EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY

Author

Greil, R., primary, Fraser, G., additional, Leber, B., additional, Marks, R., additional, Quaresmini, G., additional, Middeke, J. Moritz, additional, Semenzato, G., additional, Schary, W., additional, Boyer, M., additional, Breuleux, M., additional, Crompton, N., additional, Humphrey, K., additional, and Marlton, P., additional

Published
2019
Full Text
View/download PDF

17. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the 'Rete Ematologica Lombarda'

Author

Molteni, A, Riva, M, Borin, L, Bernardi, M, Pelizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R, Morra, E, Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Morra E, Molteni, A, Riva, M, Borin, L, Bernardi, M, Pelizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R, Morra, E, Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, and Morra E

Abstract

5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.

Published
2016

18. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients

Author

Tedeschi, A, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, M, Anastasia, A, Rossini, F, Cortelezzi, A, Nador, G, Scarfo, L, Cairoli, R, Frustaci, A, Dalceggio, D, Picardi, P, de Paoli, L, Orlandi, E, Rambaldi, A, Massaia, M, Gaidano, G, Montillo, M, Tedeschi A., Rossi D., Motta M., Quaresmini G., Rossi M., Coscia M., Anastasia A., Rossini F., Cortelezzi A., Nador G., Scarfo L., Cairoli R., Frustaci A. M., Dalceggio D., Picardi P., de Paoli L., Orlandi E., Rambaldi A., Massaia M., Gaidano G., Montillo M., Tedeschi, A, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, M, Anastasia, A, Rossini, F, Cortelezzi, A, Nador, G, Scarfo, L, Cairoli, R, Frustaci, A, Dalceggio, D, Picardi, P, de Paoli, L, Orlandi, E, Rambaldi, A, Massaia, M, Gaidano, G, Montillo, M, Tedeschi A., Rossi D., Motta M., Quaresmini G., Rossi M., Coscia M., Anastasia A., Rossini F., Cortelezzi A., Nador G., Scarfo L., Cairoli R., Frustaci A. M., Dalceggio D., Picardi P., de Paoli L., Orlandi E., Rambaldi A., Massaia M., Gaidano G., and Montillo M.

Published
2015

19. THE MDS/MPN PATIENTS TREATED WITH 5-AZACITIDINE: A CLINICAL REAL LIFE EXPERIENCE

Author

Riva, M, Molteni, A, Borin, L, Bernardi, M, Pellizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R, Riva M, Molteni A, Borin L, Bernardi M, Pellizzari A, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Riva, M, Molteni, A, Borin, L, Bernardi, M, Pellizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R, Riva M, Molteni A, Borin L, Bernardi M, Pellizzari A, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, and Cairoli R

Published
2015

20. THE EFFICACY OF THE 5-AZACITIDINE IN THE THERAPY-RELATED MYELOID NEOPLASIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE

Author

Riva, M, Molteni, A, Borin, L, Bernardi, M, Pellizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R, Riva M, Molteni A, Borin L, Bernardi M, Pellizzari A, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Riva, M, Molteni, A, Borin, L, Bernardi, M, Pellizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R, Riva M, Molteni A, Borin L, Bernardi M, Pellizzari A, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, and Cairoli R

Published
2015

21. THE EFFICACY OF THE 5-AZACITIDINE IN THE THERAPY-RELATED MYELOID NEOPLASIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE

Author

Riva, M., Molteni, A., Borin, L., Bernardi, M., Pellizzari, A., Freyrie, A., Della Porta, M., Nichelatti, M., Ravano, E., Quaresmini, G., Jacopo Mariotti, Caramazza, D., Ubezio, M., Guarco, S., Gigli, F., Greco, R., Cairoli, R., Riva, M, Molteni, A, Borin, L, Bernardi, M, Pellizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, and Cairoli, R

Subjects
hematology
Published
2015

22. A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS

Author

Montillo, M, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, M, Anastasia, A, Rossini, F, Cortellezzi, A, Nador, N, Scarfo, L, Cairoli, R, Frustaci, A, Dal Ceggio, D, Picardi, P, De Paoli, L, Orlandi, E, Rambaldi, A, Morra, M, Massaia, M, Tedeschi, A, Montillo M, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortellezzi A, Nador N, Scarfo L, Cairoli R, Frustaci AM, Dal Ceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Morra M, Massaia M, Tedeschi A, Montillo, M, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, M, Anastasia, A, Rossini, F, Cortellezzi, A, Nador, N, Scarfo, L, Cairoli, R, Frustaci, A, Dal Ceggio, D, Picardi, P, De Paoli, L, Orlandi, E, Rambaldi, A, Morra, M, Massaia, M, Tedeschi, A, Montillo M, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortellezzi A, Nador N, Scarfo L, Cairoli R, Frustaci AM, Dal Ceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Morra M, Massaia M, and Tedeschi A

Published
2014

23. A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY)

Author

Ghia, P., primary, Scarfò, L., additional, Coscia, M., additional, Sancetta, R., additional, Ferrario, A., additional, Tedeschi, A., additional, Farina, L., additional, Laurenti, L., additional, Orlandi, E., additional, Reda, G., additional, Motta, M., additional, Carlo Stella, C., additional, Massaia, M., additional, Quaresmini, G., additional, Rossini, F., additional, Ladetto, M., additional, Gaidano, G., additional, Rossi, V., additional, and Montillo, M., additional

Published
2017
Full Text
View/download PDF

24. EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME.

Author

Frustaci, A. M., Montillo, M., Rossi, D., Zinzani, P. L., Motta, M., Gaidano, G., Quaresmini, G., Scarfò, L., Pietrasanta, D., Coscia, M., Deodato, M., Zamprogna, G., Cairoli, R., Stüssi, G., Zucca, E., Pileri, S., Zenz, T., and Tedeschi, A.

Subjects
RICHTER syndrome, ATEZOLIZUMAB, VENETOCLAX, DIFFUSE large B-cell lymphomas, DNA repair
Abstract

RS mutation profile was tested on pre-treatment cell free DNA. Rate of unmeasurable MRD and impact of mutations and chronic lymphocytic leukemia-RS clonal relation on outcomes will be presented at the meeting. B Introduction: b Chemoimmunotherapy is the standard first line treatment of diffuse large B-cell lymphoma (DLBCL) variant of Richter syndrome (RS). [Extracted from the article]

Published
2023
Full Text
View/download PDF

25. MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)

Author

Scarfo, L, Quaresmini, G, Mauro, Fr, Orlandi, E, Reda, G, Laurenti, L, Coscia, Marta, Ambrosetti, A, Murru, R, Trentin, L, Guelill, A, Visco, C, Morabito, F, Frustaci, A, Ciolli, S, Rossini, F, Cuneo, A, Gozzetti, A, Scortechini, I, Pane, F, Zinzani, Pl, Ferrara, F, Mannina, D, Marasca, R, Pierri, I, Specchia, G, Chiarenza, A, Zallio, F, Molica, S, De Paoli, L, Torreggiani, A, Brugiatelli, M, Semenzato, G, Innocenti, I, Picardi, P, Pizzolo, G, Foa, R, Rambaldi, A, and Ghia, P.

Published
2015

27. High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis

Author

Rosti, V, Bonetti, E, Bergamaschi, G, Campanelli, R, Guglielmelli, P, Maestri, M, Magrini, U, Massa, M, Tinelli, C, Viarengo, G, Villani, L, Primignani, M, Vannucchi, Am, Frassoni, F, Barosi, G, Agimm, Investigators, INCLUDING VANNUCCHI AM, Antonioli, E, Bartalucci, N, Biamonte, F, Bogani, C, Bosi, A, Fjerza, R, Malevolti, E, Pancrazzi, A, Pieri, L, Spolverini, A, Susini, Mc, Tozzi, L, Bortoluzzi, Stefania, Bisognin, A, Coppe, A, Marchioli, R, Azzan, C, Badalucco, S, Balduini, A, Carolei, A, Currao, M, Isgrã’, Ma, Lupo, Ml, Magni, V, Cazzola, M, Bernasconi, P, Boggi, S, Elena, C, Gallãœ, A, Malcovati, L, Pascutto, C, Passamonti, F, Pietra, D, Rumi, E, Dejana, E, Corada, M, Giannotta, M, Rambaldi, A, Ferrari, Ml, Finazzi, G, Finazzi, Mc, Magri, M, Quaresmini, G, Montalvo, Ml, Ricci, C, Salmoiraghi, S, Spinelli, O, Amaru, A, Golay, J, Cilloni, D, Arruga, F, Bracco, E, Carturan, S, Gaidano, V, Guerrasio, A, Pradotto, M, Manfredini, R, Bianchi, E, Montanari, M, Salati, S, Tagliafico, E, Tenedini, E, and Zini, R.

Subjects
Male, Pathology, myeloproliferative neoplasm, Gastroenterology, Cohort Studies, Hematologic Cancers and Related Disorders, splanchnic vein thrombosis, Hemoglobins, Polycythemia vera, Molecular Cell Biology, Odds Ratio, Splanchnic Circulation, Polycythemia Vera, Aged, 80 and over, Venous Thrombosis, Thrombocytosis, Likelihood Functions, Multidisciplinary, Hematology, Middle Aged, Venous thrombosis, Oncology, Medicine, Female, Cellular Types, Research Article, Adult, medicine.medical_specialty, Clinical Pathology, Science, Sensitivity and Specificity, Myeloproliferative Disorders, Diagnostic Medicine, Internal medicine, medicine, Humans, Myelofibrosis, Biology, Myeloproliferative neoplasm, Aged, Essential thrombocythemia, business.industry, Endothelial Cells, Cancers and Neoplasms, Odds ratio, medicine.disease, Thrombocytopenia, Cross-Sectional Studies, Splanchnic vein thrombosis, business, Biomarkers, General Pathology
Abstract

Increased mobilization of circulating endothelial progenitor cells may represent a new biological hallmark of myeloproliferative neoplasms. We measured circulating endothelial colony forming cells (ECFCs) in 106 patients with primary myelofibrosis, fibrotic stage, 49 with prefibrotic myelofibrosis, 59 with essential thrombocythemia or polycythemia vera, and 43 normal controls. Levels of ECFC frequency for patient's characteristics were estimated by using logistic regression in univariate and multivariate setting. The sensitivity, specificity, likelihood ratios, and positive predictive value of increased ECFC frequency were calculated for the significantly associated characteristics. Increased frequency of ECFCs resulted independently associated with history of splanchnic vein thrombosis (adjusted odds ratio = 6.61, 95% CI = 2.54-17.16), and a summary measure of non-active disease, i.e. hemoglobin of 13.8 g/dL or lower, white blood cells count of 7.8×10(9)/L or lower, and platelet count of 400×10(9)/L or lower (adjusted odds ratio = 4.43, 95% CI = 1.45-13.49) Thirteen patients with splanchnic vein thrombosis non associated with myeloproliferative neoplasms were recruited as controls. We excluded a causal role of splanchnic vein thrombosis in ECFCs increase, since no control had elevated ECFCs. We concluded that increased frequency of ECFCs represents the biological hallmark of a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. The recognition of this disease category copes with the phenotypic mimicry of myeloproliferative neoplasms. Due to inherent performance limitations of ECFCs assay, there is an urgent need to arrive to an acceptable standardization of ECFC assessment.

Published
2010

28. Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)

Author

Angelucci, E, Santini, V, Tucci, Aad, Quaresmini, G, Finelli, C, Volpe, A, Quarta, G, Rivellini, F, Sanpaolo, G, Cilloni, D, Salvi, F, Caocci, G, Molteni, A, Vallisa, D, Voso, Maria Teresa, Fenu, S, Borin, L, Latte, G, Alimena, G, Storti, Sergio, Piciocchi, A, Fazi, P, Vignetti, M, Tura, S., Storti, S (ORCID:0000-0002-4374-3985), Angelucci, E, Santini, V, Tucci, Aad, Quaresmini, G, Finelli, C, Volpe, A, Quarta, G, Rivellini, F, Sanpaolo, G, Cilloni, D, Salvi, F, Caocci, G, Molteni, A, Vallisa, D, Voso, Maria Teresa, Fenu, S, Borin, L, Latte, G, Alimena, G, Storti, Sergio, Piciocchi, A, Fazi, P, Vignetti, M, Tura, S., and Storti, S (ORCID:0000-0002-4374-3985)

Abstract

In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.

Published
2014

29. L’emblema della mobilità. Per una pedagogia della dignità umana

Author

QUARESMINI, G., Sandrini, Simona, Sandrini, Simona (ORCID:0000-0003-0356-3004), QUARESMINI, G., Sandrini, Simona, and Sandrini, Simona (ORCID:0000-0003-0356-3004)

Abstract

Un settore strategico nel concepire il vivere sostenibile è quello dei trasporti. La mobilità si configura come luogo strategico di politiche ambientali e di investimento socioeconomico, di orientamento e formazione per integrare in modo fruttuoso infrastrutture tecnologiche, naturalistiche e sociali.

Published
2012

30. Rapid reconstitution of functionally active 6- sulfoLacNAc+ dendritic cells ( slanDCs) of donor origin following allogeneic haematopoietic stem cell transplant.

Author

Mimiola, E., Marini, O., Perbellini, O., Micheletti, A., Vermi, W., Lonardi, S., Costantini, C., Meneghelli, E., Andreini, A., Bonetto, C., Vassanelli, A., Cantini, M., Zoratti, E., Massi, D., Zamo', A., Leso, A., Quaresmini, G., Benedetti, F., Pizzolo, G., and Cassatella, M. A.

Subjects
DENDRITIC cells, GRAFT versus host disease, HEMATOPOIETIC stem cell transplantation, PLASMACYTOMA, TUMOR necrosis factors, IMMUNE reconstitution inflammatory syndrome, CYCLOSPORINS, THERAPEUTICS
Abstract

The role of dendritic cells ( DCs) and macrophages in allogeneic haematopoietic stem cell transplant ( HSCT) is critical in determining the extent of graft- versus-host response. The goal of this study was to analyse slanDCs, a subset of human proinflammatory DCs, in haematopoietic stem cell ( HSC) sources, as well as to evaluate their 1-year kinetics of reconstitution, origin and functional capacities in peripheral blood ( PB) and bone marrow ( BM) of patients who have undergone HSCT, and their presence in graft- versus-host disease ( GVHD) tissue specimens. slanDCs were also compared to myeloid (m) DCs, plasmacytoid (p) DCs and monocytes in HSC sources and in patients' PB and BM throughout reconstitution. slanDCs accounted for all HSC sources. In patients' PB and BM, slanDCs were identified from day +21, showing median frequencies comparable to healthy donors, donor origin and kinetics of recovery similar to mDCs, pDCs, and monocytes. Under cyclosporin treatment, slanDCs displayed a normal pattern of maturation, and maintained an efficient chemotactic activity and capacity of releasing tumour necrosis factor ( TNF)-α upon lipopolysaccharide ( LPS) stimulation. None the less, they were almost undetectable in GVHD tissue specimens, being present only in intestinal acute GVHD samples. slanDCs reconstitute early, being donor-derived and functionally competent. The absence of slanDCs from most of the GVHD-targeted tissue specimens seems to rule out the direct participation of these cells in the majority of the local reactions characterizing GVHD. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

31. THE MDS/MPN PATIENTS TREATED WITH 5-AZACITIDINE: A CLINICAL REAL LIFE EXPERIENCE

Author

Riva, M., Molteni, A., Borin, L., Bernardi, M., Pellizzari, A., Freyrie, A., Della Porta, M., Nichelatti, M., Ravano, E., Quaresmini, G., Jacopo Mariotti, Caramazza, D., Ubezio, M., Guarco, S., Gigli, F., Greco, R., Cairoli, R., Riva, M, Molteni, A, Borin, L, Bernardi, M, Pellizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, and Cairoli, R

Subjects
hematology

34. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Ellen van der Spek, Emili Montserrat, Talha Munir, Paolo Ghia, Shaimaa El-Ashwah, Andreas Glenthøj, Viola Maria Popov, Sanne H. Tonino, Ann Janssens, Michel van Gelder, Lara Malerba, Rocío García-Serra, Alberto Lopez-Garcia, Juan-Gonzalo Correa, Christos Demosthenous, Idanna Innocenti, Maria Papaioannou, Lydia Scarfò, Antonio Cuneo, Francesca Romana Mauro, Sabina Kersting, Robin Foà, David Donaldson, Livio Trentin, Roberta Murru, Panagiotis Baliakas, Marina Motta, Deepesh Lad, Yervand K Hakobyan, Paolo Sportoletti, Lucrecia Yáñez San Segundo, Alicia Enrico, Elżbieta Kalicińska, Ewa Wasik-Szczepanek, Martin Spacek, Tamar Tadmor, Enrico Lista, Roel van Kampen, Lorella Orsucci, Michael Doubek, Yair Herishanu, Blanca Espinet, Jose Angel Hernandez-Rivas, Inga Piskunova, Ozren Jakšić, Georgios Karakatsoulis, Tomasz Wróbel, Oana Stanca, Luca Laurenti, Martin Andres, Roberto Marasca, Mark-David Levin, Giovanni Del Poeta, Miguel Arturo Pavlovsky, Maria Dimou, Monia Marchetti, Ivana Milosevic, Gianluigi Reda, Tobias Herold, David Allsup, Raul Cordoba, Andrea Visentin, Maria Gomes da Silva, Angela Ferrari, Antonella Capasso, Juan Marquet, Francesca Maria Quaglia, Candida Vitale, Mattias Mattsson, Marta Coscia, Moritz Fürstenau, Lucia Farina, Niki Stavroyianni, Marta Morawska, Arnon P. Kater, Mónica Baile, Gevorg Saghumyan, Carolina Cuéllar-García, Jacopo Olivieri, Darko Antic, Raquel Nunes Rodrigues, Alejandro Alonso Cabrero, Henrik Frederiksen, Alessandro Rambaldi, Marzia Varettoni, Amit Shrestha, Оlga B Kalashnikova, Thomas Chatzikonstantinou, José A. García-Marco, Martin Simkovic, Linda Katharina Karlsson, Odit Gutwein, Mohamed A. Yassin, Rosa Ruchlemer, Eva Gimeno, Kristian Qvist, Fatima Miras, Gilad Itchaki, Maria Rosaria De Paolis, Maria Efstathopoulou, Doreen te Raa, Barbara Eichhorst, Dominique Bron, Jorge Labrador, Gian Matteo Rigolin, Myriam Foglietta, Massimo Gentile, Sofia Chatzileontiadou, Carsten Utoft Niemann, Anargyros Kapetanakis, Kostas Stamatopoulos, Lorenzo De Paoli, Giulia Quaresmini, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Chatzikonstantinou, T., Kapetanakis, A., Scarfo, L., Karakatsoulis, G., Allsup, D., Cabrero, A. A., Andres, M., Antic, D., Baile, M., Baliakas, P., Bron, D., Capasso, A., Chatzileontiadou, S., Cordoba, R., Correa, J. -G., Cuellar-Garcia, C., De Paoli, L., De Paolis, M. R., Del Poeta, G., Demosthenous, C., Dimou, M., Donaldson, D., Doubek, M., Efstathopoulou, M., Eichhorst, B., El-Ashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., Frederiksen, H., Furstenau, M., Garcia-Marco, J. A., Garcia-Serra, R., Gentile, M., Gimeno, E., Glenthoj, A., Gomes da Silva, M., Gutwein, O., Hakobyan, Y. K., Herishanu, Y., Hernandez-Rivas, J. A., Herold, T., Innocenti, I., Itchaki, G., Jaksic, O., Janssens, A., Kalashnikova, Оb., Kalicinska, E., Karlsson, L. K., Kater, A. P., Kersting, S., Labrador, J., Lad, D., Laurenti, L., Levin, M. -D., Lista, E., Lopez-Garcia, A., Malerba, L., Marasca, R., Marchetti, M., Marquet, J., Mattsson, M., Mauro, F. R., Milosevic, I., Miras, F., Morawska, M., Motta, M., Munir, T., Murru, R., Niemann, C. U., Rodrigues, R. N., Olivieri, J., Orsucci, L., Papaioannou, M., Pavlovsky, M. A., Piskunova, I., Popov, V. M., Quaglia, F. M., Quaresmini, G., Qvist, K., Reda, G., Rigolin, G. M., Ruchlemer, R., Saghumyan, G., Shrestha, A., Simkovic, M., Spacek, M., Sportoletti, P., Stanca, O., Stavroyianni, N., Tadmor, T., Te Raa, D., Tonino, S. H., Trentin, L., Van Der Spek, E., van Gelder, M., van Kampen, R., Varettoni, M., Visentin, A., Vitale, C., Wasik-Szczepanek, E., Wrobel, T., San Segundo, L. Y., Yassin, M., Coscia, M., Rambaldi, A., Montserrat, E., Foa, R., Cuneo, A., Stamatopoulos, K., Ghia, P., Experimental Immunology, Clinical Haematology, AII - Cancer immunology, and CCA - Cancer Treatment and Quality of Life

Subjects
Chronic lymphocytic leukaemia, Cancer Research, medicine.medical_specialty, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, medicine.medical_treatment, Chronic lymphocytic leukemia, CLL, COVID-19, 610 Medicine & health, Disease, Lower risk, COVID-19 (Malaltia), Severity of Illness Index, Article, NO, law.invention, Risk Factors, law, Internal medicine, Case fatality rate, Mortalitat, medicine, Humans, Hematologi, Chronic, Mortality, Science & Technology, Leukemia, SARS-CoV-2, business.industry, Vaccination, B-Cell, Leucèmia, COVID-19, Immunosuppression, Hematology, Prognosis, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Survival Analysis, Intensive care unit, Lymphocytic, Oncology, business, Life Sciences & Biomedicine
Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p

Published
2021
Full Text
View/download PDF

35. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report

Author

Marina Motta, Daniela Gottardi, Vittorio Stefoni, Daniela Pietrasanta, Gianluigi Reda, Lydia Scarfò, Gian Matteo Rigolin, Annalisa Chiarenza, Francesca Maria Quaglia, Maria Chiara Tisi, Alessandro Sanna, Luciano Levato, Robin Foà, Monica Leone, Livio Trentin, Massimo Gentile, Monia Marchetti, Adalberto Ibatici, Enrico Derenzini, Roberta Murru, Antonio Cuneo, Angela Ferrari, Giulia Quaresmini, Francesca Romana Mauro, Annamaria Giordano, Lucia Farina, Myriam Foglietta, Paolo Sportoletti, Lara Malerba, Alessandro Gozzetti, Roberto Marasca, Federico Chiurazzi, Lorenzo De Paoli, Francesca Re, Giovanni Del Poeta, Andrea Ferrario, Marta Coscia, Luca Laurenti, Lorella Orsucci, Marzia Varettoni, Claudia Baratè, Giuseppa Penna, Valter Gattei, Jacopo Olivieri, Cuneo, A., Rigolin, G. M., Coscia, M., Quaresmini, G., Scarfo', L., Mauro, F. R., Motta, M., Quaglia, F. M., Trentin, L., Ferrario, A., Laurenti, L., Reda, G., Ferrari, A., Pietrasanta, D., Sportoletti, P., Re, F., De Paoli, L., Foglietta, M., Giordano, A., Marchetti, M., Farina, L., Del Poeta, G., Varettoni, M., Chiurazzi, F., Marasca, R., Malerba, L., Ibatici, A., Tisi, M. C., Stefoni, V., Leone, M., Barate, C., Olivieri, J., Murru, R., Gentile, M., Sanna, A., Gozzetti, A., Gattei, V., Gottardi, D., Derenzini, E., Levato, L., Orsucci, L., Penna, G., Chiarenza, A., and Foa, R.

Subjects
Male, Cancer Research, 2019-20 coronavirus outbreak, Time Factors, targeted agents, Coronavirus disease 2019 (COVID-19), Chronic lymphocytic leukemia, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), NO, COVID‐19, Pandemic, medicine, Humans, Chronic, chronic lymphocytic leukemia, COVID-19, vaccination, Letter to the Editor, Aged, Leukemia, business.industry, SARS-CoV-2, Vaccination, B-Cell, Disease Management, Hematology, General Medicine, Middle Aged, medicine.disease, Prognosis, Virology, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytic, Settore MED/15 - MALATTIE DEL SANGUE, Oncology, Italy, Female, business
Published
2021

36. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Tobias Herold, Martin Andres, Gimena Dos Santos, Livio Trentin, Monia Marchetti, Antonio Cuneo, Robin Foà, Vladimir Strugov, Sunil Iyengar, Ozren Jakšić, Mark-David Levin, Angela Ferrari, Francesca Romana Mauro, Candida Vitale, Martin Spacek, Olga Kalashnikova, Eugene Nikitin, Ann Janssens, Constantine S. Tam, Julio Delgado, Maria Papaioannou, Barbara Pocali, Davide Rossi, Marina Motta, Niki Stavroyianni, Myriam Foglietta, Alicia Enrico, Carolina Cuéllar-García, Lara Malerba, Mónica Baile, Lydia Scarfò, Ellen van der Spek, Paolo Sportoletti, Maria Rosaria De Paolis, Mihnea Zdrenghea, Macarena Ortiz Pareja, Annalisa Chiarenza, Sabina Kersting, Fatima Miras, Yair Herishanu, Emili Montserrat, Marta Coscia, Giuseppe Rossi, Jose Angel Hernandez-Rivas, Carsten Utoft Niemann, Alessandro Rambaldi, Amit Shrestha, Roberto Marasca, Rosa Ruchlemer, Marzia Varettoni, Dominique Bron, Juan Marquet, Eva Gimeno, Viola Maria Popov, Massimo Gentile, Mohamed A. Yassin, Kostas Stamatopoulos, Lorenzo De Paoli, Thomas Chatzikonstantinou, Giulia Quaresmini, Luca Laurenti, Lucia Farina, Arnon P. Kater, Nimish Shah, Elisabeth Vandenberghe, José A. García-Marco, Oana Stanca, Giovanni Del Poeta, Martin Simkovic, Yervand K Hakobyan, Enrico Lista, Michael Doubek, Gilad Itchaki, Talha Munir, Paolo Ghia, Ewa Wasik-Szczepanek, Gianluigi Reda, Francesca Maria Quaglia, Maria Dimou, Gábor Barna, Lorella Orsucci, Gian Matteo Rigolin, Scarfo', L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernandez-Rivas, J. A., Miras, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., Iyengar, S., Janssens, A., Marasca, R., Ferrari, A., Cuellar-Garcia, C., Itchaki, G., Spacek, M., De Paoli, L., Laurenti, L., Levin, M. -D., Lista, E., Mauro, F. R., Simkovic, M., Van Der Spek, E., Vandenberghe, E., Trentin, L., Wasik-Szczepanek, E., Ruchlemer, R., Bron, D., De Paolis, M. R., Del Poeta, G., Farina, L., Foglietta, M., Gentile, M., Herishanu, Y., Herold, T., Jaksic, O., Kater, A. P., Kersting, S., Malerba, L., Orsucci, L., Popov, V. M., Sportoletti, P., Yassin, M., Pocali, B., Barna, G., Chiarenza, A., dos Santos, G., Nikitin, E., Andres, M., Dimou, M., Doubek, M., Enrico, A., Hakobyan, Y., Kalashnikova, O., Ortiz Pareja, M., Papaioannou, M., Rossi, D., Shah, N., Shrestha, A., Stanca, O., Stavroyianni, N., Strugov, V., Tam, C., Zdrenghea, M., Coscia, M., Stamatopoulos, K., Rossi, G., Rambaldi, A., Montserrat, E., Foa, R., Cuneo, A., Ghia, P., Experimental Immunology, Clinical Haematology, and CCA - Cancer Treatment and Quality of Life

Subjects
0301 basic medicine, Male, Chronic lymphocytic leukaemia, Cancer Research, Chronic Lymphocytic Leukemia, COVID-19, Chronic lymphocytic leukemia, Comorbidity, Severity of Illness Index, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, Obinutuzumab, Surveys and Questionnaires, hemic and lymphatic diseases, 80 and over, Viral, Chronic, 610 Medicine & health, Immunodeficiency, Aged, 80 and over, Leukemia, Mortality rate, Age Factors, Hematology, Middle Aged, Prognosis, Lymphocytic, Oncology, 030220 oncology & carcinogenesis, Infectious diseases, Female, Coronavirus Infections, medicine.drug, Bendamustine, medicine.medical_specialty, Pneumonia, Viral, Antineoplastic Agents, Article, NO, 03 medical and health sciences, Betacoronavirus, Internal medicine, Severity of illness, medicine, Humans, Chronic Lymphocytic Leukemia, Pandemics, Protein Kinase Inhibitors, Aged, Retrospective Studies, SARS-CoV-2, Venetoclax, business.industry, Adenine, B-Cell, COVID-19, Odds ratio, Pneumonia, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Settore MED/15 - MALATTIE DEL SANGUE, 030104 developmental biology, Pyrazoles, Pyrimidines, chemistry, business
Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Published
2020

37. Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation

Author

Lucia Farina, Francesco Zallio, Daniele Vallisa, Andrea Ferrario, Francesco Barretta, M. Montillo, Lydia Scarfò, Francesco Onida, C. Salvetti, Benedetto Bruno, Massimo Magagnoli, G. Quaresmini, Marta Coscia, Francesca Patriarca, AM M. Frustaci, Paolo Corradini, Renato Fanin, Gianluigi Reda, Farina, L., Barretta, F., Scarfo', L., Bruno, B., Patriarca, F., Frustaci, A. M., Coscia, M., Salvetti, C., Quaresmini, G., Fanin, R., Onida, F., Magagnoli, M., Zallio, F., Vallisa, D., Reda, G., Ferrario, A., Corradini, P., and Montillo, M.

Subjects
Oncology, medicine.medical_specialty, Transplantation Conditioning, Allogeneic transplantation, BCR inhibitor, Chronic lymphocytic leukemia, chemistry.chemical_compound, Internal medicine, medicine, Humans, Transplantation, Homologous, Cumulative incidence, Progression-free survival, Retrospective Studies, Transplantation, Venetoclax, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome, chemistry, Ibrutinib, Rituximab, business, Stem Cell Transplantation, medicine.drug
Abstract

Refractory/early relapsed and 17p deletion/p53 mutation (del(17p)/TP53mut)-positive chronic lymphocytic leukemia (CLL) has been conventionally considered a high-risk disease, potentially eligible for treatment with allogeneic stem cell transplantation (alloSCT). In this multicenter retrospective analysis of 157 patients, we compared the outcomes of patients with high-risk CLL treated with alloSCT, a B-cell receptor pathway inhibitor (BCRi), and both. Seventy-one patients were treated with BCRis, 67 patients underwent reduced-intensity conditioning alloSCT, and 19 received alloSCT with a BCRi before and/or after transplantation. Inverse probability of treatment weighting analyses were performed to compare the alloSCT and no-alloSCT groups; in the 2 groups, 5-year OS, PFS, and cumulative incidence of nonrelapse mortality (NRM) and relapse were 40% versus 60% (P = .096), 34% versus 17% (P = .638), 28% versus 5% (P = .016), and 38% versus 83% (P = .005), respectively. Patients treated with alloSCT plus BCRi had a 3-year OS of 83%. The 3-year OS and NRM by year of alloSCT, including patients treated with BCRi, were 53% and 17% in 2000 to 2007, 55% and 30% in 2008 to 2012, and 72% and 18% in 2013 to 2018. In conclusion, the combination of pathway inhibitors and alloSCT is feasible and may further improve the outcome of high-risk CLL patients.

Published
2020

38. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the 'Rete Ematologica Lombarda'

Author

Alessandra Freyrie, Emanuele Ravano, Enrica Morra, Roberto Cairoli, Jacopo Mariotti, Marta Ubezio, Rosa Greco, Matteo G. Della Porta, Domenica Caramazza, Massimo Bernardi, Marta Riva, Simona Guarco, Alfredo Molteni, Lorenza Borin, Giulia Quaresmini, Michele Nichelatti, Federica Gigli, Anna Maria Pelizzari, Molteni, A, Riva, M, Borin, L, Bernardi, M, Pelizzari, A, Freyrie, A, Della Porta, M, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R, and Morra, E

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Antimetabolites, Antineoplastic, Azacitidine, Disease, Comorbidity, Kaplan-Meier Estimate, Prognostic indice, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, Young adult, Psychiatry, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Myelodysplastic syndromes, Retrospective cohort study, 5-Azacytidine, Hematology, Middle Aged, medicine.disease, Leukemia, Myeloid, Acute, Oncology, ROC Curve, International Prognostic Scoring System, 030220 oncology & carcinogenesis, Myelodysplastic Syndromes, High risk myelodysplastic syndrome, Oligoblastic acute myeloid leukemia, Female, business, Risk assessment, 030215 immunology, medicine.drug
Abstract

5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.

Published
2016

39. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients

Author

Ester Orlandi, Marco Montillo, Marianna Rossi, Lydia Scarfò, Giulia Quaresmini, Gianluca Gaidano, Agostino Cortelezzi, Guido Nador, Antonella Anastasia, Lorenzo De Paoli, Davide Rossi, Marina Motta, Daniela Dalceggio, Anna Maria Frustaci, Fausto Rossini, Marta Coscia, Massimo Massaia, Alessandro Rambaldi, Alessandra Tedeschi, Roberto Cairoli, Paola Picardi, Tedeschi, A, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, M, Anastasia, A, Rossini, F, Cortelezzi, A, Nador, G, Scarfo, L, Cairoli, R, Frustaci, A, Dalceggio, D, Picardi, P, de Paoli, L, Orlandi, E, Rambaldi, A, Massaia, M, Gaidano, G, and Montillo, M

Subjects
Oncology, medicine.medical_specialty, Chronic lymphocytic leukemia, Cyclophosphamide, Elderly, Ofatumumab, Pentostatin, Hematology, Cyclophosphamide, Chronic lymphocytic leukemia, Ofatumumab, chemistry.chemical_compound, Elderly, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, Pentostatin, Online Only Articles, business.industry, Hematology, medicine.disease, Fludarabine, Leukemia, chemistry, Immunology, Rituximab, business, Untreated Chronic Lymphocytic Leukemia, medicine.drug
Abstract

There is a significant need to develop an efficient treatment, without sacrificing efficacy, for older fit patients with chronic lymphocytic leukemia (CLL) as fludarabine, cyclophosphamide and rituximab (FCR) have very often led to treatment-related toxicities, causing delay or therapy

Published
2015

40. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.

Author

Tedeschi A, Frustaci AM, Condoluci A, Coscia M, Chiarle R, Zinzani PL, Motta M, Gaidano G, Quaresmini G, Scarfò L, Catania G, Deodato M, Jones R, Tabanelli V, Griggio V, Stüssi G, Calleri A, Pini K, Cairoli R, Zenz T, Signori A, Zucca E, Rossi D, and Montillo M

Subjects
Humans, Female, Male, Aged, Middle Aged, Prospective Studies, Aged, 80 and over, Adult, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse mortality, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Sulfonamides administration & dosage, Sulfonamides adverse effects, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Abstract

Background: The diffuse large B-cell lymphoma (DLBCL) variant of Richter transformation (DLBCL-RT) is typically chemoresistant with poor prognosis. Aiming to explore a chemotherapy-free treatment combination that triggers anti-tumour immune responses, we conducted a phase 2 study of atezolizumab (a PD-L1 inhibitor) in combination with venetoclax and obinutuzumab in patients with DLBCL-RT., Methods: This was a prospective, open-label, multicentre, single-arm, investigator-initiated, phase 2 study in 15 hospitals in Italy and Switzerland. Eligible patients had a confirmed diagnosis of chronic lymphocytic leukaemia or small lymphocytic lymphoma as per the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria with biopsy-proven transformation to DLBCL; had not previously received treatment for DLBCL-RT, although they could have received chronic lymphocytic leukaemia therapies; were aged 18 years or older; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. No previous treatment with any of the drugs in the triplet combination was allowed. Patients received 35 cycles of 21 days of intravenous obinutuzumab (100 mg on day 1, 900 mg on day 2, 1000 mg on day 8 and day 15 of cycle 1; 1000 mg on day 1 of cycles 2-8) and intravenous atezolizumab (1200 mg on day 2 of cycle 1 and 1200 mg on day 1 of cycles 2-18), and continuous oral venetoclax (ramp-up from 20 mg/day on day 15 of cycle 1 according to chronic lymphocytic leukaemia schedule, then 400 mg/day from day 1 of cycle 3 to day 21 of cycle 35). The primary endpoint was overall response rate at day 21 of cycle 6 in the intention-to-treat population. We considered an overall response rate of 67% or more to be clinically active, rejecting the null hypothesis of a response of 40% or less. The study is registered with ClinicalTrials.gov, NCT04082897, and has been completed., Findings: Between Oct 9, 2019, and Oct 19, 2022, 28 patients were enrolled (12 [43%] male patients and 16 [57%] female patients). Median follow-up was 16·8 months (IQR 7·8-32·0). At cycle 6, 19 of 28 patients showed a response, yielding an overall response rate of 67·9% (95% CI 47·6-84·1). Treatment-emergent adverse events that were grade 3 or worse were reported in 17 (61%; 95% CI 40·6-78·5) of 28 patients, with neutropenia being the most frequent (11 [39%; 21·5-59·4] of 28 patients). Serious treatment-emergent adverse events were reported in eight (29%; 14·2-48·7) patients, which were most commonly infections (five [18%; 6·1-36·9] of 28 patients). There were two (7%) deaths attributable to adverse events during the study: one from sepsis and one from fungal pneumonia, which were not considered as directly treatment-related by the investigators. Six (21·4%) patients had immune-related adverse events, none of which led to discontinuation. No tumour lysis syndrome was observed., Interpretation: The atezolizumab, venetoclax, and obinutuzumab triplet combination was shown to be active and safe, suggesting that this chemotherapy-free regimen could become a new first-line treatment approach in patients with DLBCL-RT., Funding: Roche., Competing Interests: Declaration of interests AT reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Beigene, and Abbvie; support for attending meetings or travel from Abbvie, Janssen, and Beigene; and participation on a data safety monitoring board or advisory board from Janssen, Abbvie, Beigene, Lilly, and AstraZeneca. AMF reports consulting fees from Janssen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Beigene, and AstraZeneca; support for attending meetings or travel from Abbvie, Janssen, Beigene, and AstraZeneca; and participation on a data safety monitoring board or advisory board from Janssen, Beigene, and AstraZeneca. ACo reports grants or contracts from Gilead, BMS, Beigene, Abbvie, Janssen-Cilag, and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Abbvie, and Janssen-Cilag; support for attending meetings or travel from Janssen; and participation on a data safety monitoring board or advisory board from BMS. MC reports grants or contracts from Johnson & Johnson and Abbvie; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie and AstraZeneca; support for attending meetings or travel from Johnson & Johnson, Abbvie, and AstraZeneca; and participation on a data safety monitoring board or advisory board from Johnson & Johnson, Abbvie, AstraZeneca, Beigene, and GSK. RC reports support for the present manuscript from the US National Institutes of Health and National Cancer Institute (R01CA196703–01). PLZ reports consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Takeda, BMS, MSD, Roche, Gilead, Novartis, Abbvie, Beigene, Kyowa Kirin, and Janssen. MMot reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events; support for attending meetings or travel; and participation on a data safety monitoring board or advisory board from Abbvie, Janssen, and AstraZeneca. GG reports grants from Associazione Italiana per la Ricerca sul Cancro and Piano Nazionale di Ripresa e Resilienza; consulting fees from Abbvie, AstraZeneca, Beiene, Hikma, and Johnson & Johnson; and participation on a data safety monitoring board or advisory board from Abbvie, AstraZeneca, Beigene, Hikma, Johnson & Johnson, and Lilly. LS reports consulting from Abbvie, Beigene, Lilly, AstraZeneca, Janssen, and Merck; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, Beigene, Lilly, Octapharma, AstraZeneca, Janssen, and Merck; support for attending meetings or travel from AstraZeneca, Janssen, and Beigene; and participation on a data safety monitoring board or advisory board from Merck. RCa reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, Gilead, Gentilipharma, Pierre Fabre, Celgene, and Menarini stemline; support for attending meetings or travel from Pierre Fabre, Beigene, and Servier; and participation on a data safety monitoring board or advisory board from Celgene, Abbvie, Gentilipharma, and Daichi Samkio. TZ report consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, Novartis, Gilead, Janssen, AstraZeneca, Lilly, and Abbvie. EZ reports consulting fees from Abbvie, Beigene, BMS, Cures, Elly and Lilly, Incyte, Ipsen, Merck, Miltenyibiomedicine, and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, AstraZeneca, Beigene, and Gilead; support for attending meetings or travel from Abbvie; and participation on a data safety monitoring board or advisory board from Merck. DR reports support for the present manuscript from Adaptive; grants or contracts, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, AstraZeneca, Beigene, BMS, Janssen, and Lilly. All other authors declare no competing interests. No honoraria or payments were made for authorship., (Copyright © Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)

Published
2024
Full Text
View/download PDF

41. Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study.

Author

Condorelli A, Frigeni M, Quaresmini G, Salmoiraghi S, Pavoni C, Grassi A, Raviglione M, Civini A, Putelli A, Lussana F, Finazzi MC, Algarotti A, Micò MC, Spinelli O, and Rambaldi A

Subjects
Humans, Retrospective Studies, Male, Female, Middle Aged, Prognosis, Aged, Adult, Clinical Decision-Making, Transplantation, Homologous, High-Throughput Nucleotide Sequencing, Young Adult, Myelodysplastic Syndromes therapy, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes mortality, Myelodysplastic Syndromes diagnosis, Hematopoietic Stem Cell Transplantation methods
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option for patients with Myelodysplastic syndromes (MDS). For many years, the selection of patients to allogeneic HSCT has been largely based on use of the International Prognostic Scoring System-Revised (IPSS-R). However, the recent broader application of next generation sequencing in clinical practice provided an abundance of molecular data and led to the introduction of molecular prognostic scores as IPSS-Molecular (IPSS-M). In this paper, we retrospectively analyzed the outcomes of 57 consecutive MDS patients treated with allogeneic HSCT in our center. Re-stratification from IPSS-R to IPSS-M occurred in almost half of patients. The application of IPSS-M to our cohort demonstrated a stronger prognostic separation compared to IPSS-R and improved the C-index. Very high-risk IPSS-M patients showed worse outcomes following HSCT compared to high-risk patients. This study provides data supporting the need of integrating molecular information in the transplant decision making of patients with MDS. This allows an earlier and better identification of patients to whom the transplant should be advised., Competing Interests: Declaration of Competing Interest AR: Fees for consultancies and participation in meetings, boards, and symposia sponsored by Amgen, Pfizer, Novartis, Kite-Gilead, Jazz, Astellas, Abbvie, Incyte, Omeros. The other authors declare no conflict of interest., (Copyright © 2024 Elsevier Ltd. All rights reserved.)

Published
2024
Full Text
View/download PDF

42. Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL.

Author

Gritti G, Ferrari S, Lussana F, Barbui AM, Landi F, Rondi M, Putelli A, Ballardini F, Quaresmini G, Paganessi M, Pavoni C, Ghirardi A, Gotti E, Capelli C, Golay J, Introna M, and Rambaldi A

Subjects
Humans, Male, Female, T-Lymphocytes immunology, Middle Aged, Aged, Immune Reconstitution, Adult, Immunotherapy, Adoptive adverse effects, Antibodies, Bispecific therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Published
2024
Full Text
View/download PDF

43. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

Author

Visentin A, Chatzikonstantinou T, Scarfò L, Kapetanakis A, Demosthenous C, Karakatsoulis G, Minga E, Chamou D, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Besikli-Dimou S, Bron D, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Delgado J, Dimou M, Donaldson D, Catherwood M, Doubek M, Efstathopoulou M, Eichhorst B, Elashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Collado R, Gentile M, Gimeno E, Glenthøj A, da Silva MG, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova ОB, Kalicińska E, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Rigolin GM, Ruchlemer R, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Tadmor T, Capasso A, Del Poeta G, Gutwein O, Karlsson LK, Milosevic I, Mirás F, Reda G, Saghumyan G, Shrestha A, Te Raa D, Tonino SH, Van Der Spek E, van Gelder M, van Kampen R, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M, Pocali B, Vandenberghe E, Iyengar S, Varettoni M, Vitale C, Coscia M, Rambaldi A, Montserrat E, Cuneo A, Stavroyianni N, Trentin L, Stamatopoulos K, and Ghia P

Subjects
Humans, SARS-CoV-2, Post-Acute COVID-19 Syndrome, Retrospective Studies, COVID-19, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Abstract

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations., (© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

44. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.

Author

Autore F, Innocenti I, Reda G, Visentin A, Vitale C, Piciocchi A, Fresa A, Leone MMA, Farina L, Quaresmini G, Baratè C, Giordano A, Ferrari A, Angeletti I, De Paolis MR, Malerba L, Chiurazzi F, Loseto G, Catania G, Sportoletti P, Scortechini I, Moia R, Gentile M, Rigolin GM, Mattiello V, Gattei V, Coscia M, Trentin L, Foà R, Cuneo A, and Laurenti L

Subjects
Humans, Retrospective Studies, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Recurrence, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Lymphadenopathy chemically induced, Lymphadenopathy drug therapy
Abstract

Clinical or biological parameters useful to predict progression during treatment in real-life setting with ibrutinib, idelalisib and venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) are still debated. We conducted a multi-center retrospective study on CLL patients treated with ibrutinib and/or idelalisib who were switched to venetoclax for progression or due to adverse events to identify any clinical and/or biological parameters useful to predict progression during treatment with venetoclax. Of all the 128 evaluable patients, 81 had received ibrutinib prior to switching to venetoclax, 35 had received idelalisib and 12 both. When comparing the three subgroups, we did not notice any statistical difference in terms of clinical or biological features. No variable at baseline and at different time points during the follow-up (at 6, 12, 18 and 24 months) was found to predict progression nor to have significance for Progression Free Survival (PFS) in the ibrutinib group and in the idelalisib group and in subgroups according to the line of treatment. Analyzing the data of the venetoclax treatment, after a median follow up of 14.3 months, median PFS was not reached and estimated 3-year PFS was 54%. Of the 128 patients treated with venetoclax, 28 (22%) experienced progressive disease. At multivariate analysis for predictive factors for progression, lymph node diameter >56.5 mm before starting treatment emerged as an independent risk factor for progression. The lymph node predictive role for progression during venetoclax treatment could be a new parameter that deserves to be investigate in future studies., (© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

45. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

Author

Antic D, Milic N, Chatzikonstantinou T, Scarfò L, Otasevic V, Rajovic N, Allsup D, Alonso Cabrero A, Andres M, Baile Gonzales M, Capasso A, Collado R, Cordoba R, Cuéllar-García C, Correa JG, De Paoli L, De Paolis MR, Del Poeta G, Dimou M, Doubek M, Efstathopoulou M, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Lopez-Garcia A, García-Marco JA, García-Serra R, Gentile M, Gimeno E, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Kater AP, Kersting S, Koren-Michowitz M, Labrador J, Lad D, Laurenti L, Fresa A, Levin MD, Mayor Bastida C, Malerba L, Marasca R, Marchetti M, Marquet J, Mihaljevic B, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Nunes R, Olivieri J, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Reda G, Rigolin GM, Shrestha A, Šimkovič M, Smirnova S, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Te Raa D, Tomic K, Tonino S, Trentin L, Van Der Spek E, van Gelder M, Varettoni M, Visentin A, Vitale C, Vukovic V, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Carrier M, Ghia P, and Stamatopoulos K

Subjects
Aged, Anticoagulants, COVID-19 Testing, Hemorrhage, Heparin, Low-Molecular-Weight, Humans, SARS-CoV-2, Leukemia, Lymphocytic, Chronic, B-Cell, Thrombosis, Venous Thromboembolism, COVID-19 Drug Treatment
Abstract

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19., Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting., Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR = 1.022, 95%CI 1.007‒1.038 and OR = 1.025, 95%CI 1.001‒1.051, respectively), while thromboprophylaxis use was protective (OR = 0.199, 95%CI 0.061‒0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR = 1.062, 95%CI 1.017-1.109 and OR = 2.438, 95%CI 1.023-5.813, respectively)., Conclusions: Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

46. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.

Author

Deodato M, Frustaci AM, Sportoletti P, Laurenti L, Murru R, Visentin A, Reda G, Mauro FR, Quaresmini G, Vanazzi A, Vitale C, Orsucci L, Massaia M, Sanna A, Motta M, Ibatici A, Ferrarini I, Borella C, Varettoni M, Tani M, Marinoni S, Ferrario A, Zamprogna G, Montillo M, and Tedeschi A

Subjects
Antineoplastic Combined Chemotherapy Protocols adverse effects, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Humans, Pandemics, Sulfonamides, COVID-19, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Published
2022
Full Text
View/download PDF

47. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.

Author

Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, Motta M, Quaglia FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P, Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G, Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatici A, Tisi MC, Stefoni V, Leone M, Baratè C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D, Derenzini E, Levato L, Orsucci L, Penna G, Chiarenza A, and Foà R

Subjects
Aged, COVID-19 prevention & control, COVID-19 transmission, COVID-19 virology, Disease Management, Female, Humans, Italy epidemiology, Leukemia, Lymphocytic, Chronic, B-Cell epidemiology, Leukemia, Lymphocytic, Chronic, B-Cell virology, Male, Middle Aged, Prognosis, Time Factors, COVID-19 complications, Leukemia, Lymphocytic, Chronic, B-Cell therapy, SARS-CoV-2 immunology, Vaccination methods
Published
2021
Full Text
View/download PDF

48. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

Author

Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, and Ghia P

Subjects
Adenine analogs & derivatives, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, COVID-19, Comorbidity, Coronavirus Infections diagnosis, Coronavirus Infections mortality, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Male, Middle Aged, Pandemics, Piperidines, Pneumonia, Viral diagnosis, Pneumonia, Viral mortality, Prognosis, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Pyrazoles pharmacology, Pyrazoles therapeutic use, Pyrimidines pharmacology, Pyrimidines therapeutic use, Retrospective Studies, SARS-CoV-2, Severity of Illness Index, Surveys and Questionnaires, Betacoronavirus, Coronavirus Infections pathology, Leukemia, Lymphocytic, Chronic, B-Cell complications, Pneumonia, Viral pathology
Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Published
2020
Full Text
View/download PDF

49. Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.

Author

Piciocchi A, Sargentini V, Cotugno F, Bontempi K, Beltrami G, Di Tucci AA, Riva M, Quaresmini G, Vallisa D, Finelli C, Borin L, Fazi P, Vignetti M, and Angelucci E

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Blood Transfusion, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes therapy, Treatment Outcome, Young Adult, Deferasirox therapeutic use, Iron Chelating Agents therapeutic use, Iron Overload drug therapy, Iron Overload etiology, Myelodysplastic Syndromes complications
Published
2019
Full Text
View/download PDF

50. FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.

Author

Fracchiolla NS, Artuso S, Cortelezzi A, Pelizzari AM, Tozzi P, Bonfichi M, Bocchio F, Gargantini L, De Rosa E, Vighi GD, Prestini L, Sammassimo S, Frungillo N, Pasquini MC, Ragazzi A, Boghi D, Pastore A, Lanzi E, Gritti G, Quaresmini G, Voltolini S, Gaiardoni R, Corti C, Vilardo MC, La Targia ML, Berini G, Magagnoli M, Bacci C, Consonni D, Rivolta AL, and Muti G

Subjects
Aged, Female, Humans, Italy, Male, Middle Aged, Drug-Related Side Effects and Adverse Reactions diagnosis, Hematologic Neoplasms complications, Pharmacovigilance, Quality of Life psychology
Abstract

Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project "FarmaREL" has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned. The ADRs occurring in haematological patients were collected electronically and then analysed with multiple logistic regression. Between January 2009 and December 2011, 887 reports were collected. The number of ADRs was higher in older adults (528; 59%), in male (490; 55%), and in non-Hodgkin lymphoma patients (343; 39%). Most reactions were severe (45% required or prolonged hospitalization), but in most cases, they were fully resolved at the time of reporting. According to Schumock and Thornton criteria, a percentage of ADRs as high as 7% was found to be preventable versus 2% according to reporter opinion. Patients' haematological diagnosis, not age or gender, resulted to be the variable that most influenced ADR, in particular severity and outcome. The employment of personnel specifically dedicated to pharmacovigilance is a successful strategy to improve the number and quality of ADR reports. "FarmaREL", the first programme of active pharmacovigilance in oncohaematologic patients, significantly contributed to reach the WHO "Gold Standard" for pharmacovigilance in Lombardy, Italy., (Copyright © 2017 John Wiley & Sons, Ltd.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results